### The trustworthiness and impact of trial preprints for COVID-19

## decision-making: A methodological study

1

2

3 Dena Zeraatkar 4 Department of Biomedical Informatics, Harvard Medical School 5 Department of Health Research Methods, Evidence, and Impact, McMaster University 6 Tyler Pitre 7 Department of Internal Medicine, McMaster University 8 Gareth Leung 9 Faculty of Medicine, University of Ottawa 10 Ellen Cusano 11 Cumming School of Medicine, University of Calgary 12 Arnav Agarwal 13 Department of Medicine, McMaster University 14 Faran Khalid 15 Department of Medicine, McMaster University 16 Zaira Escamilla 17 Department of Health Research Methods, Evidence, and Impact, McMaster University 18 Matthew Cooper 19 Department of Medicine, University of Alberta 20 Maryam Ghadimi 21 Department of Health Research Methods, Evidence, and Impact, McMaster University 22 Ying Wang 23 Department of Health Research Methods, Evidence, and Impact, McMaster University 24 Francisca Verdugo 25 Epistemonikos Foundation, Santiago, Chile 26 Gabriel Rada 27 Epistemonikos Foundation, Santiago, Chile 28 Elena Kum 29 Department of Health Research Methods, Evidence, and Impact, McMaster University 30 Anila Qasim 31 Department of Health Research Methods, Evidence, and Impact, McMaster University 32 Jessica J Bartoszko 33 Department of Health Research Methods, Evidence, and Impact, McMaster University 34 Reed Siemieniuk 35 Department of Health Research Methods, Evidence, and Impact, McMaster University 36 Chirag J. Patel 37 Department of Biomedical Informatics, Harvard Medical School 38 Gordon Guyatt 39 Department of Health Research Methods, Evidence, and Impact, McMaster University 40 Romina Brignardello-Petersen 41 Department of Health Research Methods, Evidence, and Impact, McMaster University 42 43 Running head: trustworthiness and impact of COVID-19 trial preprints 44 Disclaimers: None.

45 Funding: This study was supported by the Canadian Institutes of Health Research CIHR-IRSC:057900132 and Coronavirus Rapid Research Funding Opportunity - OV2170359. DZ is funded by a Banting 46 Postdoctoral Fellowship. 47 Competing interests: None 48 49 **Data:** Data is available at https://osf.io/9adxb/. 50 Acknowledgements: None. 51 Authors' Contributions: DZ, RS, and RBP conceptualized the study. JJB, FV, GR, and AQ screened studies 52 for eligibility. TP, GL, EC, AA, FK, ZE, MC, MG, YW, EK, JJB, and AQ collected data. DZ drafted the first 53 version of the manuscript. All authors reviewed the manuscript and provided important intellectual 54 input. 55 Word count: 5,240 56

59

60

61

62

63

64

65

66

67 68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86 87 Abstract Purpose: To assess the trustworthiness and impact of preprint trial reports during the COVID-19 pandemic. Data sources: WHO COVID-19 database and the L-OVE COVID-19 platform by the Epistemonikos Foundation (up to August 3<sup>rd</sup>, 2021) **Design:** We compare the characteristics of COVID-19 trials with and without preprints, estimate time to publication of COVID-19 preprint reports, describe discrepancies in key methods and results between preprint and published trial reports, report the number of retracted preprints and publications, and assess whether including versus excluding preprint reports affects meta-analytic estimates and the certainty of evidence. For the effects of eight therapies on mortality and mechanical ventilation, we performed meta-analyses including preprints and excluding preprints at 1 month, 3 months, and 6 months after the first trial addressing the therapy became available either as a preprint or publication (120 meta-analyses in total). **Results:** We included 356 trials, 101 of which are only available as preprints, 181 as journal publications, and 74 as preprints first and subsequently published in journals. Half of all preprints remain unpublished at six months and a third at one year. There were few important differences in key methods and results between trial preprints and their subsequent published reports. We identified four retracted trials, three of which were published in peer-reviewed journals. With two exceptions (2/60; 3.3%), point estimates were consistent between meta-analyses including versus excluding preprints as to whether they indicated benefit, no appreciable effect, or harm. There were nine comparisons (9/60; 15%) for which the rating of the certainty of evidence differed when preprints were included versus excluded, for four of these comparisons the certainty of evidence including preprints was higher and for five of these comparisons the certainty of evidence including preprints was lower. Limitations: The generalizability of our results is limited to COVID-19. Preprints that are subsequently published in journals may be the most rigorous and may not represent all trial preprints. Conclusion: We found no compelling evidence that preprints provide less trustworthy results than published papers. We show that preprints remain the only source of findings of many trials for several months, a length of time that is unacceptable in a health emergency. We show that including preprints may affect the results of meta-analyses and the certainty of evidence. We encourage evidence users to consider data from preprints in contexts in which decisions are being made rapidly and evidence is being produced faster than can be peer-reviewed.

#### Summary Box 1

88

89

90

91

What is already known on this topic

- Clinicians and decision-makers need rapidly available and credible data addressing the comparative effectiveness of treatments and prophylaxis for COVID-19.
- Investigators have adopted preprint servers, which allow the rapid dissemination of research findings before publication in peer-reviewed journals.

#### What this study adds

- We found no compelling evidence that preprints provide less trustworthy results than published papers.
- We show that including preprints may affect the results of meta-analyses and the certainty of
  evidence and we encourage evidence users to consider data from preprints in contexts in
  which decisions are being made rapidly and evidence is being produced faster than can be
  peer-reviewed.

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

**Background** During the COVID-19 pandemic, the scientific community adopted preprint servers, which allow investigators to disseminate research findings before publication in peer-reviewed journals. Authors of seminal COVID-19 trials, for example, representing massive international collaborations, such as RECOVERY (1-4) and SOLIDARITY (5, 6), reported their results in preprints before subsequent publication in journals. Growing interest in preprints predates the COVID-19 pandemic (7, 8). Researchers and evidence users have raised concerns that the traditional publication model is slow, peer review may not always improve the quality of manuscripts, journals impede dissemination due to paywalls and high publication fees and encourage publication bias by prioritizing statistically significant or anomalous findings—issues preprints may avoid (9-15). Despite these concerns, and the potential of preprints to address them, because preprints may result in the dissemination of provisional findings that contain important errors that, presumably, published papers do not, the medical community has been cautious regarding their adoption (16, 17). Authors of systematic reviews, guideline developers, and other decision makers face a trade-off when considering preprints: on the one hand, including preprints could reduce the credibility of evidence syntheses and risk serious errors if important differences appear in published reports; on the other, including preprints may increase the precision of estimates; allow timely dissemination of research, and may minimize the effects of publication bias. Knowledge of the extent to which preprints may accelerate the dissemination of findings, the frequency and nature of discrepancies between pre-prints and subsequent published reports, frequency of retractions of preprints compared to publications, and the impact preprints on meta-analytic estimates could inform the trade-off that evidence users face. Our study capitalizes on our living systematic reviews and network meta-analyses (SRNMAs) of drug treatments, antiviral antibodies and cellular therapies, and prophylaxis for COVID-19—an initiative launched in July 2020 that provides real-time summaries addressing the comparative effectiveness of treatments and prophylaxis for COVID-19—to report on the characteristics, trustworthiness—that is, complete and consistent reporting of key aspects of the methods and results between preprint and published trial reports—and impact of COVID-19 trial preprint reports (18-20).

122123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

Methods We submitted a protocol for this study for publication on September 7<sup>th</sup>, 2021. Because the protocol was still under review at the time the study was completed, we withdrew the protocol for publication and present it in Supplement 1. Search Our study uses the search strategy of our living SRNMA that includes daily searches in the World Health Organization (WHO) COVID-19 database—a comprehensive multilingual source of global published and preprint literature on COVID-19 (https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/). Prior to its merge with the WHO COVID-19 database on 9 October 2020, we searched the US Centers for Disease Control and Prevention (CDC) COVID-19 Research Articles Downloadable Database. A validated machine learning model facilitates efficient identification of randomized trials (21).Our search is supplemented by ongoing surveillance of living evidence retrieval services, including the Living Overview of the Evidence (L-OVE) COVID-19 platform by the Epistemonikos Foundation (https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d) and the Systematic and Living Map COVID-19 Norwegian Health on Evidence by the Institute of Public (https://www.fhi.no/en/gk/systematic-reviews-hta/map/). Using the above sources, we also monitor for retraction notices and concerns regarding trial integrity. Supplement 2 includes additional details of our search strategy. Study selection As part of the living SRNMA, pairs of reviewers, following calibration exercises to ensure sufficient agreement, work independently and in duplicate to screen titles and abstracts of search records and subsequently the full texts of records determined potentially eligible at the title and abstract screening stage. Reviewers also link preprint reports with their subsequent publications based on trial registration numbers, the names of investigators, recruiting centres and countries, dates of recruitment, and other trial characteristics. When links between preprints and subsequent publications are unclear, we contact the author for confirmation. Reviewers resolve discrepancies by discussion or, when necessary, by adjudication with a third-party reviewer. Eligible preprint and peer reviewed articles report trials that randomize patients with suspected, probable, or confirmed COVID-19 to drug treatments, antiviral antibodies and cellular therapies, placebo, or standard care or trials that randomize healthy participants exposed or unexposed to COVID-

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

19 to prophylactic drugs, standard care, or placebo. We do not apply any restrictions on severity of illness, setting, or language of publication but do exclude trials that report on nutritional interventions, traditional Chinese herbal medicines without standardization in formulations and dosing across batches, and non-drug supportive care interventions. We did not perform a sample size calculation since we included all eligible trial reports identified through our living SRNMAS up to August 3<sup>rd</sup>, 2021. Data collection As part of the living SRNMA, for each eligible trial, pairs of reviewers, following training and calibration exercises, independently extract trial characteristics, methods, and results using a standardized, pilot tested data extraction form. To assess risk of bias, reviewers, following training and calibration exercises, use a revision of the Cochrane tool for assessing risk of bias in randomized trials (RoB 2.0) (22) (Supplement 3). Reviewers resolve discrepancies by discussion and, when necessary, by adjudication with a third party. For the current study, pairs of trained and calibrated reviewers, working independently and in duplicate and using a pilot-tested form, collected data on differences in key methods and results between preprint and published trial reports. Key methods included description of the randomization process and allocation concealment, blinding of patients and healthcare providers, extent of and handling of missing outcome data, blinding of outcome assessors and adjudicators, and prespecification of outcomes and analyses. Key results included number of participants analyzed and number of events in each trial arm for dichotomous outcomes and number of participants analyzed, means or medians and measures of variability for continuous outcomes. We focused on the same outcomes as our living SRNMA: mortality, mechanical ventilation, adverse events leading to discontinuation, viral clearance, admission to hospital, viral clearance, hospital length of stay, ICU length of stay, duration of mechanical ventilation, time to symptom resolution or clinical improvement, time to viral clearance, days free from mechanical ventilation, and time to viral clearance. For preprints with more than one version, we extracted data from the first version of the preprint, which is the least likely to have been modified in response to peer review. Because risk of bias may vary across outcomes, for this analysis we present risk of bias judgements corresponding to the following hierarchy of outcomes for therapy trials: mortality, mechanical ventilation, duration of hospitalization, time to symptom resolution or clinical improvement, and virologic outcomes. For prophylaxis trials, we used the following hierarchy: mortality, laboratory

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

confirmed and suspected COVID-19 infection, and laboratory confirmed COVID-19 infection. These hierarchies represent the relative importance of outcomes based on rankings made by the linked WHO guideline panel (23). Data synthesis and analysis Characteristics and risk of bias of trials We compare the characteristics and risk of bias of trials with preprints, trials with publications, and trials first posted as a preprint and subsequently published by calculating differences in proportions and associated confidence intervals. Time to publication of trial preprints We calculated the median time from a trial being posted on a preprint server to its eventual publication in a journal and used Kaplan-Meier curves and log-rank tests to assess whether source of funding, number of centers and participants, early termination for benefit, intensity of care (inpatient versus outpatient), and severity (mild/moderate versus severe/critical COVID-19), statistically significant primary or secondary outcomes (based on cut-offs defined by the authors or, when no cut-offs were defined, based on a cut-off of p<0.05 or confidence intervals not including the null), and risk of bias (trials rated at low versus high risk of bias) are predictive of time to publication of trial preprints. Differences between preprint and published trial reports Among trial preprints that were subsequently published in a peer reviewed journal, we described the number and types of discrepancies in key methods and results between preprint and published trial reports. For discrepancies in the reporting of key methods, we report the number and percentage of the changes between preprints and publications that affected risk of bias judgements—changes that we considered to be critical. Retractions We compare the number of preprint and published trials that have been retracted. Comparison of meta-analyses including versus excluding evidence from preprints For trials that report on interventions that have been addressed by the linked WHO living guideline (23) up to August 3<sup>rd</sup> 2021 (i.e., corticosteroids, remdesivir, lopinavir-ritonavir, hydroxychloroquine, ivermectin, IL-6 receptor blockers, and convalescent plasma for treatment and hydroxychloroquine for prophylaxis) and the two most commonly reported outcomes (i.e., mortality, mechanical ventilation),

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

we conducted pairwise frequentist random-effects meta-analyses with the restricted maximum likelihood estimator including versus excluding evidence from preprints at one, three, and six months after the first trial addressing the drug of interest was made public, either via preprint or publication. We also conducted an analysis including versus excluding evidence from preprints at August 3<sup>rd</sup>—the longest timepoint at which we collected data. For hydroxychloroquine for prophylaxis, because mechanical ventilation was not an outcome of interest for prophylaxis trials, we report only on mortality. To facilitate interpretation, we calculated absolute effects. To calculate absolute effects, for drug treatments, we used mortality data from the CDC and data on ventilation from the International Severe Acute Respiratory and Emerging Infection COVID-19 database (24-26). For prophylaxis, we used the event rate among all participants randomized to standard care or placebo to calculate the baseline risk. We compared the direction of effect between meta-analyses including versus excluding preprints. We considered the direction of effect different if one point estimate suggested no effect and another suggested a benefit or harm or if one point estimate suggested benefit and another suggested harm. For treatment, we considered an effect to be beneficial if the point estimate indicated a reduction in risk of mortality of 1% or greater or a reduction in risk of mechanical ventilation of 2% or greater for treatment. For prophylaxis, we considered an effect to be beneficial if the point estimate indicated a reduction in risk of mortality of 0.5% or greater. For treatment, we considered an effect to be harmful if the point estimate indicated that there was an increase in risk of mortality of 1% or greater or an increase in risk of mechanical ventilation of 2% or greater. For prophylaxis, we considered an effect to be harmful if the point estimate indicated an increase in risk of mortality of 0.5% or greater for prophylaxis. Otherwise, we inferred that there was no important effect. The GRADE approach provided the framework for assessing certainty of evidence and informed whether including versus excluding preprint reports led to differences in ratings of the overall certainty of evidence, judgments related to specific GRADE domains, and whether differences in ratings are likely to impact decision making (i.e., evidence rated as high/moderate versus low/very low) (27). A minimally contextualized approach informed ratings of imprecision (28). We considered any effect on mortality and mechanical ventilation to be important. Thresholds of 1% risk difference for mortality and a 2% risk difference for mechanical ventilation informed judgements of minimal or no treatment effect. For prophylaxis and mortality, we used a 0.5% risk difference (28).

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

We performed all statistical analysis in R (version 4.03, R Foundation for Statistical Computing), using the meta, forestplot, survival, and survminer packages. Patient/Public Involvement Patients were involved in outcome selection, interpretation of results, and the generation of parallel recommendations, as part of the parallel SRNMA and guidelines (23). Results Trial characteristics As of August 3<sup>rd</sup>, we identified 356 eligible trials, 101 of which were only available as preprints, 181 only available as journal publications, and 74 first available as preprints and subsequently published as journal articles. Supplement 4 presents additional details on the results of the search and Table 1 presents overall trial characteristics overall and trial characteristics stratified by publication status. Typical trials were registered, completed at the time of reporting, addressed drug therapies, enrolled less than 250 participants, reported one or more secondary outcomes that were statistically significant, and were funded by governments and/or institutions. Nearly two thirds of trials were at high risk of bias, primarily due to their open-label design. Compared to published trials without preprints, trials only available as preprints and trials first available as preprints and then subsequently published were more likely to be registered; trials only available as preprints were more likely to report on interim results, describe drug therapies compared to antiviral antibodies and cellular therapies or prophylaxis, and to have received industry funding; and trials first posted as preprints and subsequently published were more likely to have received government funding. Predictors of publication and time to publication During the 1.5 year span of this study, of 175 preprints, 74 (42.3%) were subsequently published in peerreviewed journals. Table 2 presents the proportion of preprints published up to one year and table 3 presents predictors of publication. A quarter of preprints were published in peer reviewed journals by 3 months after the preprint first became available and half by 6 months. At one year, a third of preprints remained unpublished. Preprints that received government funding, reported on inpatients, or reported on patients with severe disease were published faster than preprints that did not receive government funding, reported on outpatients, or patients with mild/moderate disease, respectively.

#### Differences between preprint and published trial reports

Forty-two trials (56.8%) had one or more discrepancies in the reporting of key methods and results

between the preprint and the later published trial report. Supplement 5 describes these discrepancies.

Thirty trials (40.5%) had one or more discrepancies in the reporting of key methods--all of which had to

do with information either missing from the preprint or the publication. The most common discrepancy

in the reporting of key methods was the description of allocation concealment, which occurred in eight

trials. Box 1 presents an example. Our judgement of risk of bias for the randomization domain changed

from 'probably high risk of bias' to 'low risk of bias' for four of these eight trials due to additional details

reported in the published report.

# Box 1: Example of a trial that reported additional information on allocation concealment in the published report

The PANAMO trial, which was initially available as a preprint on SSRN and later published in *Lancet Rheumatology*, provided additional details in the publication on allocation concealment. The publication describes central randomization with an online tool and the development of the randomization list by a third party—all of which were not reported in the preprint (29, 30).

#### **Preprint**

271

272

273

274

275

276

277

278

279

280

281

282

283

"Patients were randomly assigned in a 1:1 ratio to receive IFX-1, at a dose of 800 mg intravenously, for a maximum of seven doses, plus best supportive care, or best supportive care only. [..] Randomization was performed with an online tool within the eCRF [electronic case report form] and was stratified by study site."

#### **Publication**

"Patients were randomly assigned in a 1:1 ratio to IFX-1 plus best supportive care (the IFX-1 group) or to best supportive care only (the control group). Randomisation was done by investigators centrally with an online tool within the electronic case report form and was stratified by study site. The tool used a randomised variable block length of either 2 or 4. The randomisation list was only available to contract research organisation (Metronomia) staff involved in the production of the randomisation list and set-up of the online randomisation tool."

Other differences in the reporting of key methods were the publication reporting one or more additional statistics important for meta-analysis (e.g., IQR or SD) that were not previously reported in the preprint (n=6; 8.1%), the preprint reporting on interim results and the publication on completed trial results

(n=4; 5.4%), and the publication including a protocol and/or statistical analysis plan as a supplementary that was not previously included with the preprint (n=3; 4.1%). The overall trial rating of risk of bias, however, changed only for one trial based on additional information provided in the published report.

Thirty-one trials (41.9%) had one or more differences in the reporting of key results between preprints and publications. The most common discrepancy in the reporting of key results were changes in outcome data between preprints and publications, which was seen in 20 trials (27.0%)—though most of these discrepancies may be attributed to events accumulating in trials from the time at which the preprint was posted to when the trial was published. Box 2 presents an example.

## Box 2: Example of a trial that reported different outcome data between the preprint and publication

The RECOVERY publication on dexamethasone, for example, reported different results for mortality and mechanical ventilation—likely not because of an error in the preprint but because of events accumulating in the trial from when the preprint was posted to when it was published (2, 31).

Outcome	Preprint (31)	Publication (2)					
Mortality	Corticosteroids: 454/2104 (21.6 %)	Corticosteroids: 482/2104 (22.9%)					
	Standard care: 1065/4321 (24.6%)	Standard care: 1110/4321 (25.7%)					
Mechanical ventilation	Corticosteroids: 92/1780 (5.2%)	Corticosteroids: 110/1780 (6.2%)					
	Standard care: 258/3638 (7.1%)	Standard care: 298/3638 (8.2%)					

Despite discrepancies in outcome data being common, the magnitude and precision of effects were similar between preprints and publications. Figure 1 shows differences in results on mortality and mechanical ventilation between preprints and publications. Among all preprints with differences in outcomes, differences in relative effects did not exceed 15%, except for one trial with very few events that included just one additional event in the publication (32, 33). Other differences between preprints and publications in key results included the publication reporting an outcome that was not included in the preprint (n=11; 14.9%).

#### Retractions

We identified four retracted trials (34-41). Two trials reported on (hydroxy)chloroquine (34, 35)(36, 37), two on favipiravir (36, 37)(38, 39), and two on ivermectin (34, 35)(40, 41). One of the four trials was single-centre (40, 41) and the remainder were multi-centre trials. One of the trials was retracted when the authors noticed an error in their analysis (40, 41) and the remainder were retracted due to concerns

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

more]; very low certainty) when preprints were included.

about data fabrication or falsification (e.g., inconsistencies between the eligibility criteria and patients included in the trial, discrepancies between when the trial was reported to have been conducted and when patients were recruited, inconsistencies between the dataset and the results reported in the preprint, inconsistencies between the distribution of baseline variables and the described randomization procedure). We compared the number of retractions between preprints and journal publications. One of the retracted trials was posted as a preprint (34, 35) and the remainder were published in peerreviewed journals. Evidence synthesis including versus excluding preprint reports Table 4 presents results of meta-analyses including and excluding data from unpublished preprints for the comparison of placebo or standard care with corticosteroids, remdesivir, lopinavir-ritonavir, hydroxychloroquine, ivermectin, IL-6 receptor blockers, and convalescent plasma and mortality and mechanical ventilation at 1 month, 3 months, and 6 months after the first trial addressing the intervention was made public, either as a preprint or a publication, and at the longest point of follow-up of the trials (August 3<sup>rd</sup>). In total, we performed and assessed the certainty of evidence of 120 metaanalyses, 60 of which included preprints and 60 of which excluded preprints. Supplement 6 presents forest plots for meta-analyses. Because of insufficient data, we could not perform meta-analyses for six comparisons without preprints: mortality and mechanical ventilation, at one month, for ivermectin vs. placebo/standard care and IL-6 receptor blockers vs. placebo/standard care and mortality and mechanical ventilation, at three months, for ivermectin vs. placebo/standard care. Differences in estimates from meta-analyses including versus excluding preprints Except for two cases, across all meta-analyses including and excluding results from unpublished preprints, the point estimates were consistent as to whether they indicated benefit, no appreciable effect, or harm. The meta-analysis of corticosteroids at one month suggested a reduction in risk of mechanical ventilation when preprints were excluded (43 fewer per 1,000 people [95% CI 59.24 fewer to 22.12 fewer]; moderate certainty) and no appreciable effect when preprints were included (1.2 more per 1,000 people [95% CI 60.3 fewer to 131.1 more]; very low certainty). The meta-analysis of ivermectin at 6 months suggested no appreciable effect on risk of mechanical ventilation when preprints were excluded (2.3 fewer per 1,000 people [95% CI 52.2 fewer to 83.5 more]; low certainty) and a reduction in risk of mechanical ventilation (26.7 fewer per 1,000 people [95% CI 74.2 fewer to 75.4

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

Differences in ratings of the certainty of evidence from meta-analyses including versus excluding preprints There were nine cases for which the rating of the certainty of evidence was different when preprints were included versus excluded. For four of these nine cases, we rated the certainty of evidence including preprints higher than the evidence excluding preprints due to no serious concerns in imprecision in analyses including preprints. For five of these nine cases, we rated the certainty of evidence excluding preprints higher than the evidence including preprints, due to serious imprecision for four of five cases and due to serious imprecision and serious risk of bias for one of five cases. In six of these cases, differences in ratings of the certainty of evidence may have impacted decision-making (i.e., evidence including preprints is rated as high/moderate whereas evidence excluding preprints is rated as low/very low or vice versa). Differences in ratings of the GRADE risk of bias domain from meta-analyses including versus excluding preprints Between meta-analyses including versus excluding preprints, judgements related to the GRADE risk of bias domain differed only for the meta-analysis of remdesivir and mechanical ventilation at 6 months. We rated the meta-analysis excluding preprints to not have any concerns related to risk of bias and downgraded the meta-analysis including preprints due to serious risk of bias. Differences in ratings of the GRADE imprecision domain from meta-analyses including versus excluding preprints Between meta-analyses including versus excluding preprints, judgements related to the GRADE imprecision domain differed for 13 meta-analyses. We judged nine meta-analyses excluding preprints to have more serious concerns related to imprecision than their counterparts including preprints (i.e., additional data from preprints narrowed confidence intervals) and we judged four meta-analyses excluding preprints to have less serious concerns related to imprecision that their counterparts including preprints (i.e., additional data from preprints increased statistical heterogeneity and hence imprecision). Discussion Main findings Our study presents a detailed assessment of the trustworthiness and impact of COVID-19 trial preprint reports. We show that preprints remain the only source of findings of many trials for several months. Half of all preprints, for example, remain unpublished at six months and a third at one year—a length of

time that may be unacceptable in a health emergency like COVID-19. Preprints can importantly accelerate the time to dissemination of trial findings.

We did not find compelling evidence of important differences between preprint and published reports of trials—though preprint reports of trials that are subsequently published in journals may not be representative of all trial preprints. Further, we found retractions to occur for both preprints and publications, suggesting that publication in a peer-reviewed journal alone does not indicate trustworthiness of a trial report.

We also found that in most cases, meta-analyses including versus excluding evidence from preprints yielded consistent results and the same certainty of evidence. In a minority of circumstances, however, including preprints improved the certainty of evidence. At six months after trial data first became available, when preprints were excluded, we found low certainty evidence that IL-6 receptor blockers may reduce mortality—downgraded due to risk of bias and imprecision. Conversely, we found moderate certainty evidence IL-6 receptor blockers probably reduce mortality when preprints were included—downgraded due to risk of bias. For the case of IL-6 receptor blockers, considering evidence from preprints may have importantly accelerated the time to incorporation of IL-6 receptor blockers as part of standard care (23). In a minority of circumstances, including preprints also reduced the certainty of evidence. At one month, for example, when preprints were excluded, we found moderate certainty evidence that corticosteroids probably reduce mechanical ventilation—downgraded due to serious risk of bias—and very low certainty evidence when we included preprints—downgraded due to serious risk of bias and very serious imprecision. For the case of corticosteroids, including preprints increased heterogeneity (and hence increased imprecision), and may have misinformed evidence users.

#### *Implications*

Our findings have implications for evidence users who are concerned with the trustworthiness of preprints and for systematic reviewers and guideline developers deciding whether to consider preprint reports in systematic reviews and guideline recommendations. Our results support the overall trustworthiness of preprints and preprints as a venue through which the dissemination of trial findings may be accelerated. Peer review likely only addresses transparency of the trial reports and interpretation of results because at the time of submission the trial has already been conducted and major methodological decisions (such as whether to collect data on an outcome or whether to blind investigators) cannot be changed. We encourage systematic reviewers and guideline developers to

consider trial evidence from preprints, especially in circumstances in which decisions are being made rapidly and evidence is being produced faster than can be peer reviewed and published.

We caution, however, that preprints (and publications) may describe untrustworthy trials with fabricated or falsified data. Evidence users may consider scrutinizing both preprint and published trials for anomalies that may suggest fabrication and falsification (Examples of which are reported in Box 3) (42, 43). While such methods cannot be used to definitively identify untrustworthy trials and require subjective judgements, they may be useful to identify trials that are at high risk of such issues. Evidence users may subsequently investigate such trials further or systematic reviewers may consider sensitivity analyses excluding such trials from meta-analyses. We direct readers to other sources that describe these methods (44).

#### Box 3: Methods to assess for fabrication and falsification in clinical trials (44)

- 1. Judge whether the reported recruitment speed is feasible given local disease patterns, trial eligibility criteria, and capacity of the recruiting centres (45, 46).
- 2. Review the trial registration or protocol and assess the consistency between the registration and the manuscript in aspects of the trial that cannot be modified after completion (e.g., blinding status).
- 3. Review profiles of investigators and/or institutions involved for a history of research misconduct.
- 4. Review baseline patient characteristics and test whether reported distributions are consistent with randomization (42, 43, 47).
- 5. Review primary data, when available, for duplicate records or inconsistencies between the data and reported statistics in the trial manuscript.
- 6. Review primary data, when available, and assess whether correlations between variables are plausible (45).

#### Relation to previous work

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

- Our study is the first to present data addressing the contribution of preprints to the body of evidence addressing the comparative effectiveness of COVID-19 therapies and prophylaxis.
- Two studies have reported on differences between preprint and published study reports and citations and Altmetric attention metrics (48, 49). One study addressed publication characteristics and dissemination of COVID-19 preprints and the other spin in interpretation of results. Both studies were,

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

however, restricted to only publications up to August and October 2020—which is not representative of the current landscape of COVID-19 research and which does not include the majority of evidence being currently used to guide COVID-19 care, including critical trials addressing the effects of corticosteroids and IL-6 receptor blockers (1, 2). These studies did not compare the effects of including preprints on meta-analytic estimates and the certainty of the body of evidence, which is particularly important because evidence users use the totality of the body of evidence, rather than single studies, to make treatment decisions and recommendations (48). The COVID-19 pandemic highlighted the need for rapid dissemination of research and incited increased interest in preprint servers, which yielded to an incredible amount of research that was published on preprint servers and which made this study possible. We are not aware of studies addressing the trustworthiness or impact of preprints in other areas—though such research in other areas would also be useful. Strengths and limitations The strengths of this study include the comprehensive search for, and inclusion of preprint and published COVID-19 trial reports and rigorous data collection. The generalizability of our results is, however, limited to COVID-19. Journals have expedited the publication of COVID-19 research and have been publishing more prolifically on COVID-19 than in other areas, which may reduce opportunity for revisions between preprints and their subsequent publications and may mean time to and predictors of publication may be different than in other research areas. Although the WHO COVID-19 database is a comprehensive source of published and preprint literature, it does not include all preprint servers—though preprint servers not covered by our search address other subjects and are unlikely to include COVID-19 trials. It is likely that preprint reports of trials that are subsequently published in journals represent the most rigorous or transparently reported preprints and that they are not representative of all trial preprints. To assess preprint trustworthiness, we compared reporting of key aspects of the methods and results between preprint and published trial reports. We acknowledge, however, that published trial reports may still contain errors and that posting trial reports as preprints may allow more errors to be identified prior to final publication.

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

We report on the number of publications and preprints that were retracted. Preprints, however, may be less likely to be retracted because they may draw less attention and because preprint servers may be less likely than journals to have formal policies addressing research integrity. Our assessment of the contribution of trial preprint reports to meta-analytic estimates and their effect on the certainty of evidence was undertaken in the context of pairwise meta-analysis and the minimally contextualized approach for assessing the certainty of evidence whereas parallel guideline recommendations have been based on network meta-analyses and the fully contextualized approach (23, 28). There are no compelling reasons that our results will not be generalizable to network metaanalyses. On the other hand, there will be more differences in judgements related to the certainty of evidence in a fully contextualized framework where judgements are more dependent on the magnitude and precision of estimates. We limited our assessment of the impact of including versus excluding preprint reports on meta-analytic estimates to only interventions that have been addressed by the WHO living guideline at the time of analysis (23). While the effects of including or excluding preprints in meta-analyses may vary across interventions, our analysis addresses the interventions for which there has been sufficient interest and research to instigate guideline recommendations. Interventions informed by fewer trials may be more sensitive to including or excluding evidence from preprints. Our estimate of the time to publication of preprint reports may be overestimated if some preprint authors do not attempt to subsequently publish in peer-reviewed journals—although evidence shows that most authors of COVID-19 preprints intend to publish their findings (48). Time to publication may also be underestimated if preprints are made public later in the submission process. Finally, although we describe discrepancies in the reporting of key methods and results, we did not assess differences in the discussion or conclusion sections of trial reports. Conclusions We found no compelling evidence that preprint trial reports provide less trustworthy results than published trials. We show that including preprints may affect the results of meta-analyses and the certainty of evidence and encourage evidence users to consider data from preprints in contexts in which decisions are being made rapidly and evidence is being produced faster than can be peer reviewed and published. Skepticism may still be warranted when suspicion arises regarding falsified data (for which we provide criteria).

### 471 Tables

Table 1: Trial characteristics								
	All trials n (%)	Published trials without	Trials only available as preprints	% difference between trials only available as	P value	Trials first posted as preprints and subsequently	% difference between trials first posted as preprints and subsequently published and	P value
	N=356	preprints n (%)	n (%) N=101	preprints and published trials without preprints		published n (%)	published trials without preprints (95% Cis)	
		N=181	14-101	(95% Cis)		N=74		
Trial registered		11 202		(3370 013)				
Yes	319 (89.6%)	149 (82.3%)	97 (96.0%)	13.72% (7.0 to 20.5)	<0.001	73 (98.6%)	16.3% (10.2 to 22.5)	< 0.00
No	37 (10.4%)	32 (17.7%)	4 (4.0%)	-13.72% (-20.5 to - 7.0)	<0.001	1 (1.4%)	-16.3% (-22.5 to -10.2)	< 0.00
Study status								
Completed	268 (75.3%)	142 (78.5%)	75 (74.3%)	-4.2% (-14.6 to 6.2)	0.44	51 (68.9%)	-9.5% (-21.7 to 2.6)	0.12
Interim results	20 (5.6%)	5 (2.8%)	10 (9.9%)	7.1% (0.8 to 13.4)	0.03	5 (6.8%)	4.0% (-2.2 to 10.2)	0.21
Terminated early for benefit	2 (0.6%)	0 (0%)	2 (2.0%)	2.0% (-0.7 to 4.7)	0.15	0 (0%)	0 (0%)	1.00
Terminated early due to feasibility	66 (18.5%)	34 (18.8%)	14 (13.9%)	-4.9% (-13.7 to 3.9)	0.28	18 (24.3%)	5.5% (-5.8 to 16.9)	0.34
Type of treatment								
Drug therapy	293 (82.3%)	157 (86.7%)	77 (76.2%)	-10.5% (-20.2 to - 0.8)	0.03	59 (79.7%)	-7.0% (-17.4 to 3.4)	0.19
Prophylaxis	17 (4.8%)	7 (3.9%)	8 (7.9%)	4.0% (-1.9 to 10.0)	0.18	2 (2.7%)	-1.2% (-5.8 to 3.5)	0.64
Antiviral antibodies and cellular therapies	46 (12.9%)	17 (9.4%)	16 (15.8%)	6.5% (-1.8 to 14.7)	0.13	13 (17.6%)	8.2% (-1.5 to 17.8)	0.10
Inpatient†	252 (74.3%)	129 (72.3%)	65 (69.9%)	-4.3% (-15.6 to 7.1)	0.47	58 (80.6%)	6.4% (-4.8 to 17.6)	0.27
Severe/critical disease†	88 (26.0%)	46 (26.4%)	26 (28.0%)	1.5% (-9.7 to 12.8)	0.80	16 (22.2%)	-4.2% (-15.8 to 7.4)	0.49
Number of centers								
Single center	151 (42.4%)	86 (47.5%)	39 (38.6%)	-8.9% (-20.9 to 3.1)	0.15	26 (35.1%)	-12.4% (-25.5 to 0.7)	0.06
Multicenter	177 (49.7%)	85 (47.0%)	48 (47.5%)	0.6% (-12.0 to 12.7)	0.93	44 (59.5%)	12.5% (-0.8 to 25.8)	0.07
Median [IQR] number of participants	106 (60 to 266)	101 [60 to 208]	163 [64 to 412]			100 [60 to 249]		
Primary outcome statistically significant	151 (42.4%)	74 (40.9%)	49 (48.5%)	7.6% (-4.5 to 19.7)	0.22	28 (37.8%)	-3.1% (-16.2 to 10.1)	0.66
Any secondary outcome(s) statistically significant	186 (52.2%)	90 (49.7%)	53 (52.5%)	2.8% (-9.4 to 14.9)	0.67	43 (58.1%)	8.4% (-5.0 to 21.8)	0.22

High risk of bias due to randomization	122 (34.3%)	67 (37.0%)	34 (33.7%)	-3.4% (-15.0 to 8.2)	0.58	19 (25.7%)	-11.3% (-23.5 to 0.9)	0.07
High risk of bias due to deviations from intended intervention	214 (60.1%)	111 (61.3%)	56 (55.5%)	-5.9% (-17.9 to 6.1)	0.34	47 (63.5%)	2.2% (-10.9 to 15.3)	0.76
High risk of bias due to missing outcome data	19 (5.3%)	11 (6.1%)	5 (5.0%)	-1.1% (-6.6 to 4.4)	0.70	3 (4.1%)	-2.0% (-7.7 to 3.7)	0.50
High risk of bias due to measurement of the outcome	7 (2%)	6 (3.3%)	1 (1.0%)	-2.3% (-5.6 to 0.9)	0.16	0 (0%)	-3.3% (-5.9 to -0.7)	0.01
High risk of bias due to selective reporting	22 (6.2%)	9 (5.0%)	8 (7.9%)	3.0% (-3.2 to 9.1)	0.35	5 (6.8%)	1.8% (-4.8 to 8.3)	0.60
High risk of bias overall	228 (64%)	117 (64.6%)	61 (60.4%)	-4.2% (-16.1 to 7.6)	0.49	50 (67.6%)	2.9% (-9.8 to 15.7)	0.67
Funding*								
Industry	79 (22.2%)	32 (17.7%)	30 (29.7%)	12.0% (1.5 to 22.5)	0.02	17 (23%)	5.3% (-5.8 to 16.4)	0.35
Government	126 (35.4%)	47 (26.0%)	37 (36.6%)	10.7% (-0.7 to 22.0)	0.07	42 (56.8%)	30.8% (17.8 to 43.8)	<0.001
Institution	128 (36.0%)	69 (38.1%)	32 (31.7%)	-6.4% (-17.9 to 5.1)	0.28	27 (36.5%)	-1.6% (-14.7 to 11.4)	0.82
Not-for-profit	51 (14.3%)	24 (13.3%)	12 (11.9%)	-1.4% (-9.4 to 6.6)	0.75	15 (20.3%)	7.0% (-3.4 to 17.4)	0.19
Not reported	23 (6.5%)	12 (6.6%)	10 (9.9%)	3.3% (-3.6 to 10.1)	0.36	1 (1.4%)	-5.3% (-9.8 to -0.8)	0.02
No funding	49 (13.8%)	33 (18.2%)	10 (9.9%)	-8.3% (-16.4 to -0.2)	0.04	6 (8.1%)	-10.1% (-18.5 to -1.7)	0.02

<sup>\*</sup> Trials may be classified in more than one category.

<sup>†</sup> Estimates only include trials addressing therapy.

Table 2: Time to publication of COVID-1	9 trial preprints	473		
Time	Proportion of preprints published (%)	Cumulative proportio published		
0 to 2 weeks	3/174 (1.7%)	1.7%		
2 weeks to 1 month	5/169 (3.0%)	4.7%		
1 month to 2 months	12/162 (7.4%)	12.1%		
2 months to 3 months	19/133 (14.3%)	25.7%		
3 months to 6 months	27/98 (27.6%)	50.1%		
6 months to 1 year	9/42 (21.4%)	65.9%		
Median (95% CI) time to publication	5.9 months (5.1 to 10.3)			


	Median days (95% Cis)	P value
Funding		
Industry funding (n=47)	171 (145 to NA)	0.72
No industry funding (n=127)	219 (177 to NA)	
Government funding (n=78)	155 (120 to 192)	0.02
No government funding (n=96)	309 (183 to NA)	
Institutional funding (n=58)	136 (90 to NA)	0.14
No institutional funding (n=116)	192 (166 to NA)	
Not-for-profit funding (n=26)	110 (79 to NA)	0.07
No not-for-profit funding (n=148)	188 (161 to NA0	
Number of centers		
Single center (n=65)	undefined (130 to undefined)	0.13
Multicenter (n=90)	161 (136 to 219)	
Number of participants		
More than median (n=88)	142 (120 to NA)	0.14
Less than median (n=85)	219 (171 to NA)	
Intensity of care		
Inpatient (n=122)	110 (95 to 1440	<0.0001
Outpatient (n=38)	undefined	
Severity		
Mild/moderate (79)	182 (159 to 263)	<0.0001
Severe/Critical (42)	101 (89 to 128)	
Early termination for benefit	NA	NA
Primary outcome statistically significant		
Statistically significant (n=77)	243 (155 to undefined)	0.12
Not statistically significant (n=91)	161 (127 to 219)	
Any secondary outcomes statistically		
significant		
Statistically significant (n=96)	187 (120 to NA)	0.66
Not statistically significant (n=64)	152 (120 to NA)	
Risk of bias		
Low (n=52)	155 (124 to 187)	0.17
High (n=102)	122 (98 to 161)	


										3 m				
										dRxiv Vhich				
										iv pr				
					Excluding unpublished preprints					prepri		Including all preprints		
'Drug :ime"	Number of studies	Number of participants	MA estimate	Risk with standard care /placebo (/1000)	Risk difference (/1000 people)		GRADE	Number of studies	Number of participants	not certified by pe	Risk with stand ard care /placebo (/1000)	Risk difference (/1000 people)		GRADE
							Mortality			l crg/10.1108/98] It is mad@: 0.89 [@:82				
icos te ro i	Is						mortunty			is m				
onth	1	6425	0.89 [0.81 to 0.98]	130	14.3 fewer (24.7 fewer to 2.6 fewer)	Moderate	due to risk of bias	2	6489	0.89 [081 0.998]	130	14.3 fewer (24.7 fewer to 2.6 fewer)	Moderate	due to risk of bias
onths	5	7667	0.90 [0.83 to 0.97]	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate	due to risk of bias	6	7731	<b>a is</b> : <mark>7</mark> >	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate	due to risk of bias
nths	5	7667	0.90 [0.83 to 0.97]	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate	due to risk of bias	6	7731	<b>≘் 6                                   </b>	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate	due to risk of bias
ent	10	7959	0.90 [0.83 to 0.97]	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate	due to risk of bias	10	79 59	0.90 [ <b>©</b> \$3 <b>5</b> 0 <b>€</b> 97]	130	13 fewer (22.1 fewer to 3.9 fewer)	Moderate	due to risk of bias
desivir										1.222 or/fur nder				
onth	2	1 298	0.79 [0.59 to 1.05]	130	27.3 fewer (53.3 fewer to 6.5 more)	Moderate	due to imprecision	2	1298	0.79 [0.59 <b>0</b> 0-0005]	130	27.3 fewer (53.3 fewer to 6.5 more)	Mo derate	due to imprecision
onths	2	1 298	0.79 [0.59 to 1.05]	130	27.3 fewer (53.3 fewer to 6.5 more)	Moderate	due to imprecision	2	1298	0.79 [0.59€ojt.05]	130	27.3 fewer (53.3 fewer to 6.5 more)	Moderate	due to imprecision
onths	3	1882	0.78 [0.59 to 1.04]	130	28.6 fewer (53.3 fewer to 5.2 more)	Moderate	due to imprecision	4	7333	0.90 [0.734.25.11]	1 30	13 fewer (35.1 fewer to 14.3 more)	Low	due to imprecision (x2)
ent	5	7415	0.91 [0.75 to 1.11]	130	11.7 fewer (32.5 fewer to 14.3 more)	Low	due to imprecision (x2)	6	8247	0 92 1670 10 92 1670 10 92 1670	130	10.4 fewer (27.3 fewer to 9.1 more)	Moderate	due to imprecision
ina vir-rito	navir									oszewa szerier				
onth	1	199	0.77 [0.45 to 1.30]	130	29.9 fewer (71.5 fewer to 39 more)	Very low	due to risk of bias, imprecision (x2)	2	250	0.77 [ <b>⊡ 29.</b> 30]	130	29.9 fewer (71.5 fewer to 39 more)	Very low	due to risk of bias, imprecision (x2)
onths	2	250	0.77 [0.45 to 1.30]	130	29.9 fewer (71.5 fewer to 39 more)	Very low	due to risk of bias, imprecision (x2)	2	250	0.77 [ <b>664 530 66</b> .30]	130	29.9 fewer (71.5 fewer to 39 more)	Very low	due to risk of bias, imprecision (x2)
onths	2	250	0.77 [0.45 to 1.30]	130	29.9 fewer (71.5 fewer to 39 more)	Very low	due to risk of bias, imprecision (x2)	2	250	0.77 [ <b>○                                  </b>	130	29.9 fewer (71.5 fewer to 39 more)	Very low	due to risk of bias, imprecision (x2)
rent	7	9427	1.04 [0.95 to 1.14]	130	5.20 more (6.5 fewer to 18.2 more)	Very low	due to risk of bias, imprecision (x2)	7	9427		130	5.20 more (6.5 fewer to 18.2 more)	Very low	due to risk of bias, imprecision (x2)
droxy)chl	roquine (treatı	ment)								I, 20 licer				
onth	1	30	NA (O events)	130	NA	NA	NA	1	30	NA (B)	130	NA	NA	NA
onths	1	30	NA (O events)	130	NA	NA	NA	2	180	のでは、 NA (0 eyen来)	130	NA	NA	NA
onths	5	1287	1.16 [0.58 to 2.34]	130	20.8 more (54.6 fewer to 174.2 more)	Very low	due to risk of bias, imprecision (x3)	9	6135	1.08 [0.98206.19]	130	10.4 more (2.60 fewer to 24.7 more)	Low	due to risk of bias, imprecision
rent	19	10634	1.09 [1.00 to 1.19]	130	11.7 more (0 fewer to 24.7 more)	Low	due to risk of bias, imprecision	23	10997	<u>ay</u> 1.07 [0.98±0 <b>±</b> .17]	130	9.10 more (2.60 fewer to 22.1 more)	Low	due to risk of bias, imprecision
mectin										ght I				
onth	0	0	NA	130	NA	NA	NA	1	180	0.18 [0.0 <del>G</del> o <del>8,</del> 55]	130	106.6 fewer (122.2 fewer to 65 fewer)	Very low	due to risk of bias, imprecision (x2)
onths	0	0	NA	130	NA	NA	NA	4	517	0.33 [0.09 to ] 17]	130	87.1 fewer (118.3 fewer to 22.1 more)	Very low	due to risk of bias, imprecision (x2)
onths	1	398	0.33 [0.01 to 8.05]	130	87.1 fewer (128.7 fewer to 916.5 more)	Very low	due to risk of bias, imprecision (x3)	6	1169	5.34 [0.1 <b>±2</b> 0 <b>±</b> 00]	130	85.8 fewer (115.7 fewer to 0 fewer)	Low	due to risk of bias, imprecision
ent	5	1220	0.72 [0.28 to 1.85]	130	36.4 fewer (93.6 fewer to 110.5 more)	Very low	due to risk of bias, imprecision (x3)	9	1879	0.51 [0.23 <b>2</b> 0- <u>3</u> 13]	130	63.7 fewer (100.1 fewer to 16.9 more)	Very low	due to risk of bias, imprecision (x2)
receptor	blockers									etuity.				
onth	0	0	NA	130	NA	NA	NA	1	97	0.84 [0.46 to <b>1</b> .51]	130	20.8 fewer (70.2 fewer to 66.3 more)	Very low	due to risk of bias, imprecision (x3)
onths	2	26	0.30 [0.04 to 2.27]	130	91 fewer (124.8 fewer to 165.1 more)	V ery low	due to risk of bias, imprecision (x2)	4	435	0.88 [0.58 to 1.32]	130	15.6 fewer (54.6 fewer to 41.6 more)	Very low	due to risk of bias, imprecision (x3)
onths	6	1292	0.82 [0.67 to 1.00]	130	23.4 fewer (42.9 fewer to 0 fewer)	Low	due to risk of bias, imprecision	7	5408	0.87 [0.80 to 0.94]	130	22.1 fewer (31.2 fewer to 13 fewer)	Mo derate	due to risk of bias
rent	8	5457	0.87 [0.80 to 0.94]	130	22.1 fewer (31.2 fewer to 13 fewer)	Moderate	due to risk of bias	11	6303	0.86 [0.80 to 0.93]	130	22.1 fewer (31.2 fewer to 13 fewer)	Mo derate	due to risk of bias
ıvalescent	plasma													
onth	1	101	0.65 [0.29 to 1.46]	130	45.5 fewer (92.3 fewer to 59.8 more)	Very low	due to risk of bias, imprecision (x3)	2	187	0.60 [0.33 to 1.10]	130	52 few er (87.1 few er to 13 mor e)	Very low	due to risk of bias, imprecision (x3)
onths	1	101	0.65 [0.29 to 1.46]	130	45.5 fewer (92.3 fewer to 59.8 more)	Very low	due to risk of bias, imprecision (x3)	4	428	0.56 [0.32 to 0.97]	130	57.2 fewer (88.4 fewer to 3.90 fewer)	Very low	due to risk of bias, imprecision (x2)
onths	3	898	0.95 [0.68 to 1.33]	130	6.5 fewer (41.6 fewer to 42.9 more)	Very low	due to risk of bias, imprecision (x2)	7	1185	0.83 [0.63 to 1.11]	130	22.1 fewer (48.1 fewer to 14.3 more)	Very low	due to risk of bias, imprecision (x2)
rent	9	12962	0.98 [0.92 to 1.05]	130	2.60 fewer (10.4 fewer to 6.5 more)	Moderate	due to risk of bias	14	16073	0.98 [0.93 to 1.03]	130	2.60 fewer (9.10 fewer to 3.90 more)	Mo derat e	due to risk of bias
lroxy)chl	roquine (proph	ıylaxis)												
onth	1	744	NA (O events)	3	NA	NA	NA	1	744	NA (O events)	3	NA	NA	NA
onths	1	744	NA (O events)	3	NA	NA	NA	2	3151	0.73 [0.24 to 2.24]	3	0.8 fewer (2.3 fewer to 3.7 mor e)	High	NA
onths	4	8 569	0.73 [0.24 to 2.24]	3	0.8 fewer (2 fewer to 3.7 more)	High	NA	4	8 5 6 9	0.73 [0.24 to 2.24]	3	0.8 fewer (2 fewer to 3.7 more)	High	NA

										mec (w				
Current	4	8 5 6 9	0.73 [0.24 to 2.24]	3	0.8 fewer (2 fewer to 3.7 more)	High	NA	4	8569	0.73 [0.2/go.2/24]	3	0.8 fewer (2 fewer to 3.7 more)	High	NA
							Mechanical Ventilation			<b>V</b> P				
Corticos teroids										v prepri				
1 month	1	5418	0.75 [0.61 to 0.93]	116	43 fewer (59.24 fewer to 22.12 fewer)	Moderate	due to risk of bias	2	5472	1.01 [0.48 0 2:13]	116	1.2 more (60.3 fewer to 131.1 more)	Very low	due to risk of bias, imprecision (x2)
3 months	5	6324	0.84 [0.74 to 0.95]	116	32.56 fewer (44.16 fewer to 19.8 fewer)	Moderate	due to risk of bias	6	6378	0.85 [0.75 0.97]	116	17.4 fewer (29 fewer to 3.5 fewer)	Mo derat e	due to risk of bias
6 months	5	6324	0.84 [0.74 to 0.95]	116	32.56 fewer (44.16 fewer to 19.8 fewer)	Moderate	due to risk of bias	6	6378	0.85 [0.7	116	17.4 fewer (29 fewer to 3.5 fewer)	Mo derat e	due to risk of bias
Current	9	6576	0.88 [0.78 to 0.99]	116	27.9 2 fewer (39.52 fewer to 15.16 fewer)	Moderate	due to risk of bias	9	6576	0.88 [0.7800 999]	116	13.9 fewer (25.5 fewer to 1.2 fewer)	Mo derat e	due to risk of bias
Remdesivir										oi. oi <b>pe</b> e				
1 month	2	1001	0.59 [0.44 to 0.79]	116	47.6 fewer (65 fewer to 24.4 fewer)	High	NA	2	1001	0.59 [0.59 [0.79]	116	47.6 fewer (65 fewer to 24.4 fewer)	High	NA
3 months	2	1001	0.59 [0.44 to 0.79]	116	47.6 fewer (65 fewer to 24.4 fewer)	High	NA	2	1001	0.59 [ (3.79]	116	47.6 fewer (65 fewer to 24.4 fewer)	High	NA
6 months	3	1585	0.56 [0.42 to 0.74]	116	51 fewer (67.3 fewer to 30.2 fewer)	High	NA	4	6549	0.66 [🎧 🚣 🖸 7] مي 😿 🚫	116	39.4 fewer (68.4 fewer to 8.1 more)	Low	due to risk of bias, imprecision
Current	5	6619	0.72 [0.46 to 1.12]	116	32.5 fewer (62.6 fewer to 13.9 more)	Low	due to risk of bias, imprecision	6	7451	0.76 [055 500 004]	116	27.8 fewer (52.2 fewer to 4.6 more)	Low	due to risk of bias, imprecision
Lopinavir-ritonav	ir									0.76 (62) 5. She au: 1. She au:				
1 month	1	198	0.74 [0.38 to 1.42]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)	1	198	0.74 [0] (42]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)
3 months	1	198	0.74 [0.38 to 1.42]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)	1	198	0.74 [6] (42]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)
6 months	1	198	0.74 [0.38 to 1.42]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)	1	198	0.74 [0.38 0.342]	116	30.2 fewer (71.9 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)
Current	5	8474	1.14 [1.02 to 1.26]	116	16.2 more (2.3 fewer to 30.2 more)	Low	due to risk of bias, imprecision	5	8474	1.14 [1020]	116	16.2 more (2.3 fewer to 30.2 more)	Low	due to risk of bias, imprecision
(Hydroxy)chloroq	uine (Treatm	nent)								this ho ha				
1 month	2	642	1.14 [0.61 to 2.121	116	16.2 more (45.2 fewer to 129.9 more)	Very low	due to risk of bias, imprecision (x3)	4	4616	1.15 [ <b>6.9</b> 4% ∰ 39]	116	17.4 more (7.0 fewer to 45.2 more)	Low	due to risk of bias, imprecision
3 months	4	4693	1.17 [0.96 to 1.42]	116	19.7 more (4.6 fewer to 46.4 more)	Low	due to risk of bias, imprecision	6	6430	1.15 [6] 25:35] 4 2 3 5	116	17.4 more (3.5 fewer to 40.6 more)	Low	due to risk of bias, imprecision
6 months	7	6877	1.13 [0.96 to 1.32]	116	15.1 more (4.6 fewer to 37.1 more)	Low	due to risk of bias, imprecision	9	7417	1.11 [69 60 70.29]	116	12.8 more (4.6 fewer to 33.6 more)	Low	due to risk of bias, imprecision
Current	12	8053	1.23 [1.05 to 1.46]	116	26.7 more (5.8 more to 53.4 more)	Moderate	due to risk of bias	12	8053	1.23 [ <b>1 3 5 6 6 6 6 6 6 6 6 6 6</b>	116	26.7 more (5.8 more to 53.4 more)	Moderate	due to risk of bias
vermectin										d Apr dRxiv				
1 month	1	45	NA (O events)	116	NA	NA	NA	2	90	1.52 [0 3 7 2 3 5 .28]	116	60.3 more (107.9 fewer to 496.5 more)	Very low	due to risk of bias, imprecision $(x3)$
3 months	1	45	NA (O events)	116	NA	NA	NA	4	354	0.40 [ (57) (67) (67) (67)	116	69.6 fewer (109 fewer to 169.4 more)	Very low	due to risk of bias, imprecision (x3)
6 months	4	642	0.98 [0.55 to 1.72]	116	2.3 fewer (52.2 fewer to 83.5 more)	Low	due to imprecision (x2)	7	951	0.77 [ <b>3 6 2 2 3 6 5</b> ]	116	26.7 fewer (74.2 fewer to 75.4 more)	Very low	due to imprecision (x3)
Current	8	1464	0.94 [0.58 to 1.53]	116	7.0 fewer (48.7 fewer to 61.5 more)	Low	due to imprecision (x2)	9	1616	0.94 [0.58]	116	7.0 fewer (48.7 fewer to 61.5 more)	Low	due to imprecision (x2)
IL-6 receptor bloc	ke rs									spla				
1 month	0	0	NA	116	NA	NA	NA	1	273	0.76 [0.53 <b>1</b> 09]	116	27.8 fewer (54.5 fewer to 10.4 more)	Low	due to risk of bias, imprecision
3 months	3	49 5	0.68 [0.43 to 1.09]	116	37.1 fewer (66.1 fewer to 10.4 more)	Low	due to risk of bias, imprecision	5	1145	0.71[0.55% 元93]	116	33.6 fewer (52.2 fewer to 8.1 fewer)	Mo derat e	due to risk of bias
6 months	7	1826	0.74 [0.63 to 0.86]	116	30.2 fewer (42.9 fewer to 16.2 fewer)	Moderate	due to risk of bias	9	4000	0.82 [0.7∯0 <del>2.</del> 93] <b>⊒. @</b>	116	20.9 fewer (31.3 fewer to 8.1 fewer)	Mo derat e	due to risk of bias
Current	10	4170	0.83 [0.74 to 0.93]	116	19.7 fewer (30.2 fewer to 8.1 fewer)	Moderate	due to risk of bias	12	4560	0.83 [0.74=0.0] 92]	116	19.7 fewer (30.2 fewer to 9.3 fewer)	Mo derat e	due to risk of bias
Convalescent pla	ma									pe				
1 month	1	464	1.08 [0.59 to 1.99]	116	9.3 more (47.6 fewer to 104.4 more)	Very low	due to risk of bias, imprecision $(x2)$	3	705	0.83 [0.39 $\frac{\mathcal{S}}{2}$ .78]	116	19.7 fewer (70.8 fewer to 90.5 more)	Very low	due to risk of bias, imprecision (x2)
3 months	3	827	1.14 [0.81 to 1.61]	116	16.2 more (22 fewer to 70.8 more)	Very low	due to risk of bias, imprecision (x2)	6	1108	1.04 [0.7 🗐 🕰 42]	116	4.6 more (29 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)
6 months	4	987	1.11 [0.79 to 1.54]	116	12.8 more (24.4 fewer to 62.6 more)	Very low	due to risk of bias, imprecision (x2)	6	1108	1.04 [0.75 to 3.42]	116	4.6 more (29 fewer to 48.7 more)	Very low	due to risk of bias, imprecision (x2)
Current	8	8 252	0.98 [0.90 to 1.06]	116	2.3 fewer (11.6 fewer to 7 more)	Moderate	due to risk of bias	9	8333	0.98 [0.90 to 1.05]	116	2.3 fewer (11.6 fewer to 5.8 more)	Moderate	due to risk of bias

#### **Figures**

## Figure 1: Differences in results reported between preprints and publications for mortality (A) and mechanical ventilation (B)





#### References

- 486 1. Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone in
- Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. 2020:2020.06.22.20137273.
- 488 2. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in
- 489 Hospitalized Patients with Covid-19 Preliminary Report. N Engl J Med. 2020.
- 490 3. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine
- in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled
- 492 trial. medRxiv. 2020:2020.07.15.20151852.
- 493 4. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of Hydroxychloroquine
- in Hospitalized Patients with Covid-19. N Engl J Med. 2020;383(21):2030-40.
- 495 5. Pan H, Peto R, Karim QA, Alejandria M, Henao-Restrepo AM, García CH, et al. Repurposed
- 496 antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv.
- 497 2020:2020.10.15.20209817.
- 498 6. Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, et al.
- Repurposed Antiviral Drugs for Covid-19 Interim WHO Solidarity Trial Results. N Engl J Med. 2020.
- 500 7. Maslove DM. Medical Preprints-A Debate Worth Having, Jama. 2018;319(5):443-4.
- 501 8. Lauer MS, Krumholz HM, Topol EJ. Time for a prepublication culture in clinical research? Lancet.
- 502 2015;386(10012):2447-9.
- 503 9. Carneiro CF, Queiroz VG, Moulin TC, Carvalho CA, Haas CB, Rayêe D, et al. Comparing quality of
- reporting between preprints and peer-reviewed articles in the biomedical literature. BioRxiv.
- 505 2019:581892.
- 506 10. Walker R, Rocha da Silva P. Emerging trends in peer review-a survey. Front Neurosci.
- 507 2015;9:169.
- 508 11. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, et al. Increasing value and
- reducing waste: addressing inaccessible research. Lancet. 2014;383(9913):257-66.
- 510 12. Franco A, Malhotra N, Simonovits G. Social science. Publication bias in the social sciences:
- unlocking the file drawer. Science. 2014;345(6203):1502-5.
- 512 13. Schmucker C, Schell LK, Portalupi S, Oeller P, Cabrera L, Bassler D, et al. Extent of non-
- 513 publication in cohorts of studies approved by research ethics committees or included in trial registries.
- 514 PLoS One. 2014;9(12):e114023.
- 515 14. Scherer RW, Meerpohl JJ, Pfeifer N, Schmucker C, Schwarzer G, von Elm E. Full publication of
- results initially presented in abstracts. Cochrane Database Syst Rev. 2018;11(11):Mr000005.
- 517 15. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug
- Administration: review of publication and presentation. PLoS Med. 2008;5(11):e217; discussion e.
- 519 16. van Schalkwyk MCI, Hird TR, Maani N, Petticrew M, Gilmore AB. The perils of preprints. Bmj.
- 520 2020;370:m3111.
- 521 17. Flanagin A, Fontanarosa PB, Bauchner H. Preprints Involving Medical Research-Do the Benefits
- 522 Outweigh the Challenges? Jama. 2020;324(18):1840-3.
- 523 18. Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Izcovich A, Kum E, et al. Drug treatments for
- 524 covid-19: living systematic review and network meta-analysis. Bmj. 2020;370:m2980.
- 525 19. Siemieniuk RA, Bartoszko JJ, Díaz Martinez JP, Kum E, Qasim A, Zeraatkar D, et al. Antibody and
- 526 cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis. Bmj.
- 527 2021;374:n2231.
- 528 20. Bartoszko JJ, Siemieniuk RAC, Kum E, Qasim A, Zeraatkar D, Ge L, et al. Prophylaxis against covid-
- 19: living systematic review and network meta-analysis. Bmj. 2021;373:n949.

- 530 21. Marshall IJ, Noel-Storr A, Kuiper J, Thomas J, Wallace BC. Machine learning for identifying
- Randomized Controlled Trials: An evaluation and practitioner's guide. Res Synth Methods.
- 532 2018;9(4):602-14.
- 533 22. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for
- assessing risk of bias in randomised trials. Bmj. 2019;366:l4898.
- 535 23. Lamontagne F, Agoritsas T, Macdonald H, Leo YS, Diaz J, Agarwal A, et al. A living WHO guideline
- on drugs for covid-19. Bmj. 2020;370:m3379.
- 537 24. Centers for Disease Control and Prevention. COVIDView. A weekly surveillance summary of U.S.
- 538 COVID-19 activity 2020 [Available from: .
- 539 26. ISARIC (International Severe Acute Respiratory and Emerging Infections Consortium). COVID-19
- 540 Report: 08 June 2020. medRxiv 2020.
- 541 27. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging
- consensus on rating quality of evidence and strength of recommendations. Bmj. 2008;336(7650):924-6.
- 543 28. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, et al. The GRADE Working Group
- clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017;87:4-13.
- 545 29. Vlaar APJ, de Bruin S, Busch M, Timmermans S, van Zeggeren IE, Koning R, et al. Anti-C5a
- 546 antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19
- 547 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol.
- 548 2020;2(12):e764-e73.
- 549 30. Vlaar APJadB, Sanne and Busch, Matthias and Timmermans, Sjoerd and van Zeggeren, Ingeborg
- E. and Koning, Rutger and ter Horst, Liora and Bulle, Esther B. and van Baarle, Frank E.H.P. and van de
- Poll, Marcel C.G. and Kemper, E. Marleen and van der Horst, Iwan C.C. and Schultz, Marcus J. and Horn,
- Janneke and Paulus, Frederique and Bos, Lieuwe D. and Wiersinga, W. Joost and Witzenrath, Martin and
- Rueckinger, Simon and Pilz, Korinna and Brouwer, Matthijs C. and Guo, Ren-Feng and Heunks, Leo and
- van Paassen, Pieter and Riedemann, Niels. C. and van de Beek, Diederik, Anti-C5a Antibody (IFX-1)
- 555 Treatment of Severe COVID-19: An Exploratory Phase 2 Randomized Controlled Trial. .
- Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L, et al. Effect of Dexamethasone in
- Hospitalized Patients with COVID-19 Preliminary Report. medRxiv. 2020:2020.06.22.20137273.
- 558 32. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al.
- AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim
- Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2021;73(3):531-4.
- 561 33. Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, et al.
- 562 AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III
- Multicenter Randomized Clinical Trial. medRxiv. 2020:2020.07.26.20154724.
- 564 34. Elgazzar A, Hany B, Youssef SA, Hany B, Hafez M, Moussa H. Efficacy and Safety of Ivermectin for
- Treatment and prophylaxis of COVID-19 Pandemic. Research Square. 2021.
- 566 35. Brown N. A bug and a dilemma 2021 [Available from: .
- 567 36. Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, El Ghafar MSA, et al. Efficacy of
- favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol. 2021;166(3):949-54.
- 569 37. Dabbous HM, Abd-Elsalam S, El-Sayed MH, Sherief AF, Ebeid FFS, El Ghafar MSA, et al.
- Retraction Note to: Efficacy of favipiravir in COVID 19 treatment: a multi center randomized study.
- 571 Arch Virol. 2021:1.
- 572 38. Dabbous HM, El-Sayed MH, El Assal G, Elghazaly H, Ebeid FFS, Sherief AF, et al. Retraction Note:
- 573 Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised
- 574 controlled trial. Sci Rep. 2021;11(1):18983.
- 575 39. Dabbous HM, El-Sayed MH, El Assal G, Elghazaly H, Ebeid FFS, Sherief AF, et al. Safety and
- 576 efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled
- 577 trial. Sci Rep. 2021;11(1):7282.

- 578 40. Samaha AA, Mouawia H, Fawaz M, Hassan H, Salami A, Bazzal AA, et al. Effects of a Single Dose
- of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot
- 580 Clinical Trial in Lebanon. Viruses. 2021;13(6).
- 581 41. Samaha AA, Mouawia H, Fawaz M, Hassan H, Salami A, Bazzal AA, et al. Retraction: Samaha et
- al. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2
- Infected Subjects: A Pilot Clinical Trial in Lebanon. Viruses 2021, 13, 989. Viruses. 2021;13(11).
- 584 42. Carlisle JB. The analysis of 168 randomised controlled trials to test data integrity. Anaesthesia.
- 585 2012;67(5):521-37.
- 586 43. Carlisle JB. Data fabrication and other reasons for non-random sampling in 5087 randomised,
- controlled trials in anaesthetic and general medical journals. Anaesthesia. 2017;72(8):944-52.
- 588 44. Bordewijk EM, Li W, van Eekelen R, Wang R, Showell M, Mol BW, et al. Methods to assess
- research misconduct in health-related research: A scoping review. J Clin Epidemiol. 2021;136:189-202.
- Kirkwood AA, Cox T, Hackshaw A. Application of methods for central statistical monitoring in
- 591 clinical trials. Clin Trials. 2013;10(5):783-806.
- 592 46. van den Bor RM, Vaessen PWJ, Oosterman BJ, Zuithoff NPA, Grobbee DE, Roes KCB. A
- 593 computationally simple central monitoring procedure, effectively applied to empirical trial data with
- 594 known fraud. J Clin Epidemiol. 2017;87:59-69.
- 595 47. Carlisle JB, Dexter F, Pandit JJ, Shafer SL, Yentis SM. Calculating the probability of random
- sampling for continuous variables in submitted or published randomised controlled trials. Anaesthesia.
- 597 2015;70(7):848-58.
- 598 48. Oikonomidi T, Boutron I, Pierre O, Cabanac G, Ravaud P, the C-NMAC. Changes in evidence for
- 599 studies assessing interventions for COVID-19 reported in preprints: meta-research study. BMC Medicine.
- 600 2020;18(1):402.

- 601 49. Bero L, Lawrence R, Leslie L, Chiu K, McDonald S, J Page M, et al. Comparison of preprints and
- 602 final journal publications from COVID-19 Studies: Discrepancies in results reporting and spin in
- 603 interpretation. medRxiv. 2021:2021.04.12.21255329.